GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Eone Diagnomics Genome Center Co Ltd (XKRX:245620) » Definitions » EBIT

Eone Diagnomics Genome Center Co (XKRX:245620) EBIT : ₩-27,029 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eone Diagnomics Genome Center Co EBIT?

Eone Diagnomics Genome Center Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₩1,704 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-27,029 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eone Diagnomics Genome Center Co's annualized ROC % for the quarter that ended in Mar. 2024 was 3.27%. Eone Diagnomics Genome Center Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 15.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eone Diagnomics Genome Center Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -22.78%.


Eone Diagnomics Genome Center Co EBIT Historical Data

The historical data trend for Eone Diagnomics Genome Center Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eone Diagnomics Genome Center Co EBIT Chart

Eone Diagnomics Genome Center Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only -7,386.70 -5,899.45 -12,282.02 -19,523.61 -25,193.03

Eone Diagnomics Genome Center Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,539.73 -15,937.02 -172.24 -12,623.51 1,703.78

Competitive Comparison of Eone Diagnomics Genome Center Co's EBIT

For the Diagnostics & Research subindustry, Eone Diagnomics Genome Center Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eone Diagnomics Genome Center Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Eone Diagnomics Genome Center Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eone Diagnomics Genome Center Co's EV-to-EBIT falls into.



Eone Diagnomics Genome Center Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-27,029 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eone Diagnomics Genome Center Co  (XKRX:245620) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eone Diagnomics Genome Center Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=6815.116 * ( 1 - 2.54% )/( (204409.615 + 201319.98)/ 2 )
=6642.0120536/202864.7975
=3.27 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=173518.949 - 10405.389 - ( 9752.955 - max(0, 87548.444 - 46252.389+9752.955))
=204409.615

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Eone Diagnomics Genome Center Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6815.116/( ( (87761.445 + max(-20522.666, 0)) + (0 + max(-37225.48, 0)) )/ 2 )
=6815.116/( ( 87761.445 + 0 )/ 2 )
=6815.116/43880.7225
=15.53 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23342.555 + 10381.051 + 2183.371) - (10405.389 + 0 + 46024.254)
=-20522.666

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 38292.268) - (0 + 0 + 75517.748)
=-37225.48

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eone Diagnomics Genome Center Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-27028.983/118677.160
=-22.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eone Diagnomics Genome Center Co EBIT Related Terms

Thank you for viewing the detailed overview of Eone Diagnomics Genome Center Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Eone Diagnomics Genome Center Co (XKRX:245620) Business Description

Traded in Other Exchanges
N/A
Address
4th Floor, 291 Harmony-ro, Yeonsu-Gu, Incheon, KOR, 22014
Eeone Diagnomics Genome Center Co Ltd is engaged in developing and personalizing medicine based on Next Generation Sequencing technology and cutting edge genomics analysis. The company provides various personal genome sequencing and bioinformatics solutions to biomedical researchers, physicians and individuals seeking to understand the genetic influence of personal health and disease.

Eone Diagnomics Genome Center Co (XKRX:245620) Headlines

No Headlines